<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dantrolene: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dantrolene: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dantrolene: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9322" href="/d/html/9322.html" rel="external">see "Dantrolene: Drug information"</a> and <a class="drug drug_patient" data-topicid="12354" href="/d/html/12354.html" rel="external">see "Dantrolene: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708692"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity (capsule):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Dantrolene has a potential for hepatotoxicity; do not use in conditions other than those recommended. Symptomatic hepatitis (fatal and nonfatal) has been reported at various dose levels of the drug. The incidence reported in patients taking dosages of up to 400 mg/day is much lower than in those taking dosages of 800 mg or more per day. Even sporadic short courses of these higher dose levels within a treatment regimen markedly increase the risk of serious hepatic injury. Liver dysfunction as evidenced by blood chemical abnormalities alone (liver enzyme elevations) has been observed in patients exposed to dantrolene for varying periods of time. Overt hepatitis has occurred at varying intervals after initiation of therapy, but has been most frequently observed between the third and twelfth month of therapy. The risk of hepatic injury appears to be greater in females, patients &gt;35 years of age, and patients taking other medication(s). Spontaneous reports suggest a higher proportion of hepatic events with fatal outcome in elderly patients receiving dantrolene; however, the majority of these cases were complicated with confounding factors such as concurrent illnesses and/or concomitant potentially hepatotoxic medications. Use dantrolene only in conjunction with appropriate monitoring of hepatic function, including frequent determination of AST or ALT. If no observable benefit is derived from dantrolene after a total of 45 days, discontinue therapy. Prescribe the lowest possible effective dose for the individual patient.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F156723"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Dantrium;</li>
<li>Revonto;</li>
<li>Ryanodex</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866510"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Dantrium</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1057659"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidote, Malignant Hyperthermia</span>;</li>
<li>
<span class="list-set-name">Hyperthermia, Treatment</span>;</li>
<li>
<span class="list-set-name">Skeletal Muscle Relaxant, Nonparalytic</span></li></ul></div>
<div class="block dop drugH1Div" id="F156745"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7736e40c-8110-4e9d-8831-3a370efa607b">Malignant hyperthermia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malignant hyperthermia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Utilize actual body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-MHAUS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-MHAUS.4'])">Ref</a></span>) for dosing calculations. There is no recommended maximum total dose. Although FDA approved, routine dantrolene for the prevention of malignant hyperthermia is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33399225','lexi-content-ref-MHAUS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33399225','lexi-content-ref-MHAUS.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">If questions, contacting the MH Hotline (see below) may be helpful.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>24-hour MH Hotline (for emergencies only):</b></p>
<p style="text-indent:-2em;margin-left:8em;">United States: 1-800-644-9737</p>
<p style="text-indent:-2em;margin-left:8em;">Outside the United States: 001-209-417-3722</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Crisis:</i> Infants, Children, and Adolescents: IV: Initial: 2.5 mg/kg, then 1 or 2.5 mg/kg every 5 minutes as frequently as needed until treatment goals reached (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33399225','lexi-content-ref-MHAUS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33399225','lexi-content-ref-MHAUS.4'])">Ref</a></span>). Doses &gt;10 mg/kg may be required for patients with persistent contractures or rigidity; however, if no resolution, reassess diagnosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-MHAUS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-MHAUS.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postcrisis follow-up</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">IV: Infants, Children, and Adolescents: IV: 1 mg/kg/dose every 4 to 6 hours (preferred to minimize extravasation risk) if within 6 hours of initial reaction; if outside of 6-hour window, a higher dose of 2 or 3 mg/kg/dose may be needed. Treatment may be stopped or interval between doses increased to every 8 to 12 hours when the following criteria are met: metabolic stability for 24 hours, core temperature &lt;38°C, creatinine kinase continues to decrease, no evidence of ongoing myoglobinuria, and muscle rigidity has resolved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30768455','lexi-content-ref-MHAUS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30768455','lexi-content-ref-MHAUS.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: <b>Note:</b> Although FDA approved for this indication, expert guidelines do not recommend use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33399225','lexi-content-ref-30768455','lexi-content-ref-MHAUS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33399225','lexi-content-ref-30768455','lexi-content-ref-MHAUS.4'])">Ref</a></span>): Infants, Children, and Adolescents: Oral: 4 to 8 mg/kg/<b>day</b> in 4 divided doses for 1 to 3 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="12d51ee4-37b2-4443-a030-e0a3bd79e5b1">Spasticity, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Spasticity, chronic:</b>
<b>Note:</b> Dosing should be individualized based on patient response and tolerability. Titrate to desired effect; if no further benefit is observed at a higher dosage, decrease dose to previous lower dose. Use of the lowest dose associated with the optimal response is recommended:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;50 kg: Initial: 0.5 mg/kg/dose once or twice daily for 7 days; increase to 0.5 mg/kg/dose 3 times daily for 7 days, then increase to 1 mg/kg/dose 3 times daily for 7 days, and then increase to 2 mg/kg/dose 3 times daily; some patients may require a dose 4 times daily; maximum daily dose: 12 mg/kg/<b>day</b> up to 400 mg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1','lexi-content-ref-15023108','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1','lexi-content-ref-15023108','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">≥50 kg: Initial: 25 mg once daily for 7 days; increase to 25 mg 3 times daily for 7 days, then increase to 50 mg 3 times daily for 7 days, and then increase to 100 mg 3 times daily; some patients may require a dose 4 times daily; maximum daily dose: 400 mg/<b>day</b>.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51090511"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51090512"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; use of oral dantrolene in patients with active liver disease (hepatitis or cirrhosis) is contraindicated.</p></div>
<div class="block doa drugH1Div" id="F156727"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9322" href="/d/html/9322.html" rel="external">see "Dantrolene: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7736e40c-8110-4e9d-8831-3a370efa607b">Malignant hyperthermia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malignant hyperthermia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Administer dantrolene as soon as possible after the identification of clinical symptoms/crisis. Discontinue all malignant hyperthermia–triggering agents (eg, volatile anesthetics gases, succinylcholine) once hyperthermia crisis is recognized and administer supportive care. General treatment goals: end tidal CO<sub>2</sub> &lt;45 mm Hg, normal minute ventilation, core temperature &lt;38ºC (100.4ºF), heart rate stable and decreasing, muscular rigidity resolved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33399225','lexi-content-ref-30768455','lexi-content-ref-MHAUS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33399225','lexi-content-ref-30768455','lexi-content-ref-MHAUS.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Malignant hyperthermia crisis: IV:</b> Initial: 2.5 mg/kg; monitor patient continuously and administer repeat doses of 2.5 mg/kg every 5 minutes until symptoms subside and treatment goals are reached. Most patients will respond to a cumulative dose of ≤10 mg/kg; however, &gt;10 mg/kg may be necessary in patients with persistent contractures or rigidity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33399225','lexi-content-ref-30768455','lexi-content-ref-MHAUS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33399225','lexi-content-ref-30768455','lexi-content-ref-MHAUS.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Recurrence of malignant hyperthermia after initial treatment:</b>
<b>Note:</b> Monitor for recurrence (eg, increased muscular rigidity, inappropriate hypercarbia, unexplained metabolic acidosis, inappropriate temperature increase) in PACU/ICU for at least 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33399225','lexi-content-ref-MHAUS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33399225','lexi-content-ref-MHAUS.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV: </b>1 mg/kg every 4 to 6 hours or 0.25 mg/<b>kg</b>/hour continuous infusion for 24 hours or longer if clinically indicated; stop therapy or change dosing interval to every 8 to 12 hours when all of the following are met: metabolic stability for 24 hours, core temperature &lt;38ºC (100.4ºF), decrease CK, myoglobinuria absent, no muscle rigidity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33399225','lexi-content-ref-30768455','lexi-content-ref-MHAUS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33399225','lexi-content-ref-30768455','lexi-content-ref-MHAUS.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>MHAUS 24-hour MH Hotline (for emergencies only):</b></p>
<p style="text-indent:-2em;margin-left:6em;">United States: 1-800-644-9737.</p>
<p style="text-indent:-2em;margin-left:6em;">Outside the United States: 001-209-417-3722.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8d334dad-2d86-49f3-b1ea-ca68e9496b35">Neuroleptic malignant syndrome, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroleptic malignant syndrome, moderate to severe (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consider for use in combination with supportive care, benzodiazepines, and/or dopaminergic agents (eg, bromocriptine) in patients with severe symptoms at presentation (eg, hyperthermia, evidence of rhabdomyolysis) and for those not responding to initial withdrawal of medication and supportive care (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22732295','lexi-content-ref-27423483','lexi-content-ref-17541044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22732295','lexi-content-ref-27423483','lexi-content-ref-17541044'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b>
<b>Initial: </b>1 to 2.5 mg/kg initially; if rapid resolution of hyperthermia and rigidity is observed, may follow with 1 mg/kg every 6 hours (maximum cumulative daily dose: 10 mg/kg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27423483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27423483'])">Ref</a></span>). After the patient is stabilized and symptoms have resolved, consider taper over days to weeks rather than abrupt discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22732295','lexi-content-ref-30775657','lexi-content-ref-27423483','lexi-content-ref-17541044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22732295','lexi-content-ref-30775657','lexi-content-ref-27423483','lexi-content-ref-17541044'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="12d51ee4-37b2-4443-a030-e0a3bd79e5b1">Spasticity, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Spasticity, chronic: Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Dose should be titrated and individualized for maximum effect; use the lowest dose compatible with optimal response. Some patients may not respond until a higher daily dosage is achieved; each dose level should be maintained for 7 days to determine patient response. If no further benefit observed with the higher dose level, then decrease dosage to previous dose level. Because of the potential for hepatotoxicity, stop therapy if benefits are not evident within 45 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Initial: 25 mg once daily for 7 days; increase to 25 mg 3 times daily for 7 days, increase to 50 mg 3 times daily for 7 days, and then increase to 100 mg 3 times daily; some patients may require 100 mg 4 times daily; maximum dose: 400 mg/day</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991061"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988310"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use of oral dantrolene in patients with active liver disease (eg, hepatitis and cirrhosis) is contraindicated.</p></div>
<div class="block adr drugH1Div" id="F156696"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrioventricular block, flushing, heart failure, phlebitis (including superficial thrombophlebitis) (Brandom 2011), tachycardia, variable blood pressure</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acneiform eruption (Mowbray 2009), diaphoresis, eczematous rash, hair disease (abnormal growth), pruritus, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperkalemia (Brandom 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps, anorexia, constipation, diarrhea (including severe diarrhea), dysgeusia, dysphagia, gastric irritation (Brandom 2011), gastrointestinal hemorrhage, nausea (Brandom 2011), sialorrhea (Brandom 2011), vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Crystalluria, difficulty in micturition, erectile dysfunction, hematuria, nocturia, urinary frequency, urinary incontinence, urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, aplastic anemia, leukopenia, malignant lymphoma (lymphocytic) (Wan 1980), thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (Wilkinson 1979), hepatotoxicity (including hepatic necrosis) (Wilkinson 1979), increased liver enzymes (Wilkinson 1979)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (including erythema at injection site, injection-site phlebitis, pain at injection site, swelling at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (Brandom 2011), chills, confusion, depression, dizziness (Brandom 2011), drowsiness, fatigue (Brandom 2011), feeling abnormal, headache, insomnia, malaise, myasthenia (Brandom 2011), nervousness, seizure, speech disturbance, voice disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain, dystonia, limb pain, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, diplopia, epiphora, visual disturbance (Brandom 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (including a feeling of suffocation) (Brandom 2011), oropharyngeal spasm (Locatelli 2014), pleural effusion (with eosinophilia or pericarditis) (Miller 1984), pulmonary edema (Brandom 2011), respiratory depression, respiratory failure (Brandom 2011), respiratory insufficiency (including respiratory muscle weakness and decreased inspiratory capacity) (Javed 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F156710"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">IV: There are no contraindications listed within the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Active hepatic disease (eg, cirrhosis, hepatitis); when spasticity is used to maintain upright posture/balance in locomotion or to obtain/maintain increased function.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i> (additional contraindications not in US labeling): Hypersensitivity to dantrolene or any component of the formulation; compromised pulmonary function (eg, obstructive pulmonary disease).</p></div>
<div class="block war drugH1Div" id="F156693"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Oral: Has potential for hepatotoxicity; symptomatic hepatitis (fatal and nonfatal) has been reported. Idiosyncratic and hypersensitivity reactions (sometimes fatal) of the liver have also occurred; monitor hepatic function. Discontinue therapy if symptoms compatible with hepatitis, accompanied with abnormal LFTs or jaundice, occur or benefits are not observed within 45 days. Hepatic function usually reverts to normal upon discontinuation; if reinstitution of therapy is necessary, patients should be hospitalized and the drug initiated in very small and gradual dose increases.</p>
<p style="text-indent:-2em;margin-left:4em;">• Muscle weakness: Loss of grip strength, weakness in the legs, dyspnea, respiratory muscle weakness, dysphagia, and decreased inspiratory capacity has occurred with IV dantrolene. Patients should not ambulate without assistance until they have normal strength and balance. Monitor patients for the adequacy of ventilation and for difficulty swallowing/choking.</p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: Oral therapy may cause a photosensitivity reaction; use with caution during exposure to sunlight.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pleural effusion: Pleural effusion with associated eosinophilia may occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use oral therapy with caution in patients with severely impaired cardiac function due to myocardial disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic disease: Use oral therapy with caution in patients with history of hepatic disease or dysfunction; use is contraindicated in patients with active hepatic disease (eg, cirrhosis, hepatitis).</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Use oral therapy with caution in patients with impaired pulmonary function (particularly in obstructive pulmonary disease).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Alkaline solution; may cause tissue necrosis if extravasated (vesicant); ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Mannitol: Injection may contain mannitol.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F156704"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dantrium: 25 mg, 50 mg [DSC] [contains fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dantrium: 20 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Revonto: 20 mg (1 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as sodium [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Revonto: 20 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Intravenous, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ryanodex: 250 mg (1 ea) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F156689"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F156712"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Dantrium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $1.28</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Dantrolene Sodium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.96 - $1.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $1.56 - $1.73</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $1.95 - $2.17</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Dantrium Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $106.37</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Dantrolene Sodium Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $85.09</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Revonto Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $84.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Ryanodex Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $3,752.10</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866511"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dantrium: 25 mg [contains fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dantrium: 20 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg (1 ea)</p></div>
<div class="block exp drugH1Div" id="F156708"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">A 5 mg/mL oral suspension may be made with dantrolene capsules, a citric acid solution, and either simple syrup or syrup BP (containing 0.15% w/v methylhydroxybenzoate). Add the contents of five 100 mg dantrolene capsules to a citric acid solution (150 mg citric acid powder in 10 mL water); mix while adding the chosen vehicle in incremental proportions to <b>almost</b> 100 mL. Transfer to a calibrated bottle and add quantity of vehicle sufficient to make 100 mL. Label "shake well" and "refrigerate". Simple syrup suspension is stable for 2 days refrigerated; syrup BP suspension is stable for 30 days refrigerated.</p>
<div class="reference">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>
</div>
<div class="block admp drugH1Div" id="F52612482"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer liquid formulation (extemporaneously prepared) using an accurate measuring device; do not use household tablespoon.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">Dantrium, Revonto: Administer crisis doses by rapid IV injection, preferably in large-bore IV or central line.</p>
<p style="text-indent:-2em;margin-left:4em;">Ryanodex: Administer crisis doses by rapid IV injection; follow-up doses should be administered over ≥1 minute.</p>
<p style="text-indent:-2em;margin-left:4em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity.</p></div>
<div class="block adm drugH1Div" id="F156706"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Malignant hyperthermia crisis/recurrence: Administer as a rapid continuous IV push, through a large bore IV if possible (do not delay administration if large bore IV is not available) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-MHAUS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-MHAUS.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Other indications: Administer over at least 1 minute (Ryanodex) or 1 hour (Dantrium, Revonto) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity.</p></div>
<div class="block sts drugH1Div" id="F10460046"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Capsules: Store at 20°C to 25°C (68°F to 77°F). </p>
<p style="text-indent:-2em;margin-left:2em;">Injection, powder for reconstitution: Protect from light. Use reconstituted solution within 6 hours of preparation.</p>
<p style="text-indent:-2em;margin-left:4em;">Dantrium: Store unreconstituted vials and reconstituted solutions at 15°C to 30°C (59°F to 86°F). </p>
<p style="text-indent:-2em;margin-left:4em;">Revonto: Store unreconstituted vials and reconstituted solutions at 20°C to 25°C (68°F to 77°F). </p>
<p style="text-indent:-2em;margin-left:4em;">Ryanodex: Store unreconstituted vials at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). Store reconstituted solutions at 20°C to 25°C (68°F to 77°F). </p></div>
<div class="block usep drugH1Div" id="F53566347"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia (Dantrium, Revonto, Ryanodex: FDA approved in all ages); prevention of malignant hyperthermia in susceptible individuals (preoperative/postoperative administration) (Dantrium, Revonto, Ryanodex: FDA approved in all ages). <b>Note:</b> Although FDA approved, routine dantrolene for the prevention of malignant hyperthermia is not recommended (Hopkins 2021; MHAUS 2023).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Treatment of spasticity associated with upper motor neuron disorders such as spinal cord injury, stroke, cerebral palsy, or multiple sclerosis (FDA approved in ages ≥5 years and adults); preoperative prevention or attenuation of malignant hyperthermia in susceptible individuals who require anesthesia and/or surgery (FDA approved in ages ≥5 years and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Dantrolene prophylaxis is not routinely recommended for most malignant hyperthermia susceptible patients, provided there is immediate availability of parenteral dantrolene and adequate perioperative patient management (eg, avoiding known trigger agents [eg, anesthetics] in susceptible patients).</p></div>
<div class="block mst drugH1Div" id="F156768"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dantrium may be confused with danazol, Daraprim</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Revonto may be confused with Revatio</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F156754"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F156698"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Channel Blockers: Dantrolene may enhance the hyperkalemic effect of Calcium Channel Blockers. Dantrolene may enhance the negative inotropic effect of Calcium Channel Blockers. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexketoprofen: May enhance the adverse/toxic effect of Dantrolene.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May enhance the hepatotoxic effect of Dantrolene.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vecuronium: Dantrolene may enhance the neuromuscular-blocking effect of Vecuronium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F10460044"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Dantrolene crosses the human placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Cord blood concentrations of dantrolene are similar to those in the maternal plasma at term and dantrolene can be detected in the newborn serum at delivery. Adverse events were not observed in the newborn following maternal doses of 100 mg/day administered orally prior to delivery (Shime 1988).</p>
<p style="text-indent:0em;margin-top:2em;">Uterine atony has been reported following dantrolene injection after delivery; however, this may be due in part to the mannitol contained in the IV preparation (Shin 1995; Weingarten 1987). Untreated malignant hyperthermia (MH) is a medical emergency; treatment should not be withheld due to pregnancy. Prophylactic use of dantrolene is not routinely recommended in pregnant patients susceptible to MH prior to obstetric surgery; if use is needed, close monitoring of the mother and newborn is recommended (Krause 2004; Norman 1995; Urman 2019).</p></div>
<div class="block mopp drugH1Div" id="F53566346"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Spasticity: Motor performance should be monitored for therapeutic outcomes; nausea, vomiting, and liver function tests (baseline and at appropriate intervals thereafter) should be monitored for potential hepatotoxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">Malignant hyperthermia: Cardiac, respiratory, and blood pressure monitoring; during and postacute phase: Per MHAUS protocol, patient should be observed in an ICU for at least 24 hours since recrudescence may occur; monitor for arrhythmias; monitor vital signs (including core temperature), electrolytes, ABG, CK, end tidal CO<sub>2</sub> (EtCO<sub>2</sub>)/capnography, urine output, urine myoglobin.</p></div>
<div class="block pha drugH1Div" id="F156692"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Acts directly on skeletal muscle by interfering with release of calcium ion from the sarcoplasmic reticulum; prevents or reduces the increase in myoplasmic calcium ion concentration that activates the acute catabolic processes associated with malignant hyperthermia</p></div>
<div class="block phk drugH1Div" id="F156709"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Oral: 70% (Allen 1988)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 36.4 ± 11.7 L</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic; major metabolites are 5-hydroxy dantrolene and an acetylamino metabolite of dantrolene.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neonates (at birth): ~20 hours (Shime 1988)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Children 2 to 7 years: 10 hours (range: 8.1 to 14.8 hours) (Lerman 1989) </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adults: 4 to 11 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: IV: 1 minute post-dose (dantrolene); 24 hours post-dose (5-hydroxy dantrolene)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (45% to 50%); urine (25% as unchanged drug and metabolites)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038594"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Dantrium</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Dantrocris | Dantrolen</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Dantamacrin | Dantrolen</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Dantrium | Revonto</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Danlene | Relatro | Relaxo | Trolen</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Dantrium</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Dantrium</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Dantrolen</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Dantamacrin</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Dantrium</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Dantamacrin | Dantrium | Dantrolen</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Dantrolen</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Dantrium | Dantrolen</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Betenolmen | Dantrelax | Relatrolene</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Dantrium | Dantrium intraveineux</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Dantrium</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Dantamacrin | Dantrium | Dantrolene</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Dantrium</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Dantrolen | Dantrolene</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Dantrium</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Dantrium</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Dantrium</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Dantrium</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Anorex | Dantrolen</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Dantrolen</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Dantrium</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Dantamacrin | Dantrium | Dantrolen</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Dantrium</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Dantrium</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Dantrium | Dantrolen | Dantrolen ahn | Dantrolen campus</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Dantrium</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Dantamacrin | Dantrium | Dantrolen</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Dantrium</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Dantrium</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Dantrium</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Dantrium</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Dantrium | Dantrolen</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Dantrolen</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Dantrium</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Dantrium | Dantrolene</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Dantrolene</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Dantrium</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Allen.1">
<a name="Allen.1"></a>Allen GC, Cattran CB, Peterson RG, et al, "Plasma Levels of Dantrolene Following Oral Administration in Malignant Hyperthermia-Susceptible Patients," Anesthesiology, 1988, 69(6):900-4.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22732295">
<a name="22732295"></a>Bienvenu OJ, Neufeld KJ, Needham DM. Treatment of four psychiatric emergencies in the intensive care unit. <i>Crit Care Med.</i> 2012;40(9):2662-2670. doi:10.1097/CCM.0b013e31825ae0f8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/22732295/pubmed" id="22732295" target="_blank">22732295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21372281">
<a name="21372281"></a>Brandom BW, Larach MG, Chen MS, Young MC. Complications associated with the administration of dantrolene 1987 to 2006: a report from the North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States. <i>Anesth Analg</i>. 2011;112(5):1115-1123. doi:10.1213/ANE.0b013e31820b5f1f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/21372281/pubmed" id="21372281" target="_blank">21372281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10823104">
<a name="10823104"></a>Chamley D, Pollock NA, Stowell KM, et al, "Malignant Hyperthermia in Infancy and Identification of Novel RYR1 Mutation," <i>Br J Anaesth</i>, 2000, 84(4):500-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/10823104/pubmed" id="10823104" target="_blank">10823104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Par.1">
<a name="Par.1"></a>Dantrium capsules (dantrolene) [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; May 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Paladin.1">
<a name="Paladin.1"></a>Dantrium capsules (dantrolene) [product monograph]. St-Laurent, Quebec, Canada: Paladin Labs Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Par.2">
<a name="Par.2"></a>Dantrium Intravenous (dantrolene) [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; July 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Major.1">
<a name="Major.1"></a>Dantrolene sodium capsules [prescribing information]. Indianapolis, IN: Major Pharmaceuticals; October 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20101040">
<a name="20101040"></a>Delgado MR, Hirtz D, Aisen M, et al, "Practice Parameter: Pharmacologic Treatment of Spasticity in Children and Adolescents With Cerebral Palsy (an Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society," <i>Neurology</i>, 2010, 74(4):336-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/20101040/pubmed" id="20101040" target="_blank">20101040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9778021">
<a name="9778021"></a>Fricker RM, Hoerauf KH, Drewe J, et al, "Secretion of Dantrolene Into Breast Milk After Acute Therapy of a Suspected Malignant Hyperthermia Crisis During Cesarean Section," <i>Anesthesiology</i>, 1998, 89(4):1023-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/9778021/pubmed" id="9778021" target="_blank">9778021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20837722">
<a name="20837722"></a>Glahn KP, Ellis FR, Halsall PJ, et al, "Recognizing and Managing a Malignant Hyperthermia Crisis: Guidelines From the European Malignant Hyperthermia Group," <i>Br J Anaesth</i>, 2010, 105(4):417-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/20837722/pubmed" id="20837722" target="_blank">20837722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3240662">
<a name="3240662"></a>Guerrero RM and Shifrar KA, “Diagnosis and Treatment of Neuroleptic Malignant Syndrome,” <i>Clin Pharm</i>, 1988, 7(9):697-701.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/3240662/pubmed" id="3240662" target="_blank">3240662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33399225">
<a name="33399225"></a>Hopkins PM, Girard T, Dalay S, et al. Malignant hyperthermia 2020: guideline from the Association of Anaesthetists. <i>Anaesthesia</i>. 2021;76(5):655-664. doi:10.1111/anae.15317<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/33399225/pubmed" id="33399225" target="_blank">33399225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatiti</i>s. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20560919">
<a name="20560919"></a>Javed M, Bogdanov A. Oral dantrolene and severe respiratory failure in a patient with chronic spinal cord injury. <i>Anaesthesia</i>. 2010;65(8):855-856. doi:10.1111/j.1365-2044.2010.06409.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/20560919/pubmed" id="20560919" target="_blank">20560919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15023108">
<a name="15023108"></a>Krause T, Gerbershagen MU, Fiege M, et al, "Dantrolene -- A Review of its Pharmacology, Therapeutic Use and New Developments. <i>Anaesthesia</i>, 2004, 59(4):364-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/15023108/pubmed" id="15023108" target="_blank">15023108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20081135">
<a name="20081135"></a>Larach MG, Gronert GA, Allen GC, et al, "Clinical Presentation, Treatment, and Complications of Malignant Hyperthermia in North America From 1987 to 2006," <i>Anesth Analg</i>, 2010, 110(2):498-507.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/20081135/pubmed" id="20081135" target="_blank">20081135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lerman.1">
<a name="Lerman.1"></a>Lerman J, McLeod ME, and Strong HA, "Pharmacokinetics of Intravenous Dantrolene in Children," Anesthesiology, 1989, 70(4):625-9.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30768455">
<a name="30768455"></a>Litman RS, Smith VI, Larach MG, et al. Consensus statement of the Malignant Hyperthermia Association of the United States on unresolved clinical questions concerning the management of patients with malignant hyperthermia. <i>Anesth Analg</i>. 2019;128(4):652-659. doi:10.1213/ANE.0000000000004039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/30768455/pubmed" id="30768455" target="_blank">30768455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24725261">
<a name="24725261"></a>Locatelli F, Pozzi M, Avantaggiato P, et al. Pharyngeal spasticity due to dantrolene. <i>J Clin Pharm Ther</i>. 2014;39(4):449-451. doi:10.1111/jcpt.12161<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/24725261/pubmed" id="24725261" target="_blank">24725261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-MHAUS.1">
<a name="MHAUS.1"></a>Malignant Hyperthermia Association of the United States (MHAUS), 2019. Accessed April 11, 2019, at www.mhaus.org.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-MHAUS.2">
<a name="MHAUS.2"></a>Malignant Hyperthermia Association of the United States (MHAUS), 2020. Accessed January 29, 2020, at www.mhaus.org.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-MHAUS.3">
<a name="MHAUS.3"></a>Malignant Hyperthermia Association of the United States (MHAUS), 2021. Accessed December 20, 2021, at www.mhaus.org.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-MHAUS.4">
<a name="MHAUS.4"></a>Malignant Hyperthermia Association of the United States (MHAUS), 2023. www.mhaus.org. Accessed June 7, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6824251">
<a name="6824251"></a>May DC, Morris SW, Stewart RM, et al, “Neuroleptic Malignant Syndrome: Response to Dantrolene Sodium,” <i>Ann Intern Med</i>, 1983, 98(2):183-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/6824251/pubmed" id="6824251" target="_blank">6824251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6736987">
<a name="6736987"></a>Miller DH, Haas LF. Pneumonitis, pleural effusion and pericarditis following treatment with dantrolene. <i>J Neurol Neurosurg Psychiatry</i>. 1984;47(5):553-554. doi:10.1136/jnnp.47.5.553<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/6736987/pubmed" id="6736987" target="_blank">6736987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19187303">
<a name="19187303"></a>Mowbray M, Sinclair SA, Allan SJ. Severe acneiform eruption exacerbated by dantrolene sodium. <i>Clin Exp Dermatol</i>. 2009;34(2):248-249. doi:10.1111/j.1365-2230.2008.02797.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/19187303/pubmed" id="19187303" target="_blank">19187303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30775657">
<a name="30775657"></a>Ngo V, Guerrero A, Lanum D, et al. Emergent treatment of neuroleptic malignant syndrome induced by antipsychotic monotherapy using dantrolene. <i>Clin</i>
<i>Pract Cases Emerg Med</i>. 2019;3(1):16-23. doi:10.5811/cpcem.2018.11.39667<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/30775657/pubmed" id="30775657" target="_blank">30775657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7784032">
<a name="7784032"></a>Norman PF and Eichhorn JH, "Management of Anesthetic Complications and Emergencies in the Obstetric Patient," <i>Obstet Gynecol Clin North Am</i>, 1995, 22(1):1-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/7784032/pubmed" id="7784032" target="_blank">7784032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27423483">
<a name="27423483"></a>Pileggi DJ, Cook AM. Neuroleptic malignant syndrome.<i> Ann Pharmacother</i>. 2016;50(11):973-981. doi:10.1177/1060028016657553<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/27423483/pubmed" id="27423483" target="_blank">27423483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17222339">
<a name="17222339"></a>Reulbach U, Dütsch C, Biermann T, et al. Managing an effective treatment for neuroleptic malignant syndrome. <i>Crit Care</i>. 2007;11(1):R4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/17222339/pubmed" id="17222339" target="_blank">17222339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WorldMeds.1">
<a name="WorldMeds.1"></a>Revonto (dantrolene) [prescribing information]. Louisville, KY: US WorldMeds LLC; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2673115">
<a name="2673115"></a>Rosenberg MR, Green M. Neuroleptic malignant syndrome. Review of response to therapy. <i>Arch Intern Med</i>. 1989;149(9):1927-1931. doi:10.1001/archinte.149.9.1927<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/2673115/pubmed" id="2673115" target="_blank">2673115</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rubin.1">
<a name="Rubin.1"></a>Rubin AS and Zablocki AD, “Hyperkalemia, Verapamil, and Dantrolene,” <i>Anesthesiology</i>, 1987, 66(2):248-9.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eagle.1">
<a name="Eagle.1"></a>Ryanodex (dantrolene) [prescribing information]. Woodcliff Lake, NJ: Eagle Pharmaceuticals; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3177531">
<a name="3177531"></a>Shime J, Gare D, Andrews J, et al, "Dantrolene in Pregnancy: Lack of Adverse Effects on the Fetus and Newborn Infant," <i>Am J Obstet Gynecol</i>, 1988, 159(4):831-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/3177531/pubmed" id="3177531" target="_blank">3177531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15637010">
<a name="15637010"></a>Shin YK, Kim YD, Collea JV, et al, "Effect of Dantrolene Sodium on Contractility of Isolated Human Uterine Muscle," <i>Int J Obstet Anesth</i>, 1995, 4(4):197-200.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/15637010/pubmed" id="15637010" target="_blank">15637010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9951218">
<a name="9951218"></a>Silva RR, Munoz DM, Alpert M, et al, "Neuroleptic Malignant Syndrome in Children and Adolescents," <i>J Am Acad Child Adolesc Psychiatry</i>, 1999, 38(2):187-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/9951218/pubmed" id="9951218" target="_blank">9951218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17541044">
<a name="17541044"></a>Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. <i>Am J Psychiatry</i>. 2007;164(6):870-876. doi:10.1176/ajp.2007.164.6.870<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/17541044/pubmed" id="17541044" target="_blank">17541044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2122577">
<a name="2122577"></a>Tayeb OS, “A Serious Interaction of Dantrolene and Theophylline,” <i>Vet Hum Toxicol</i>, 1990, 32(5):442-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/2122577/pubmed" id="2122577" target="_blank">2122577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31166228">
<a name="31166228"></a>Urman RD, Rajan N, Belani K, Gayer S, Joshi GP. Malignant hyperthermia-susceptible adult patient and ambulatory surgery center: Society for Ambulatory Anesthesia and Ambulatory Surgical Care Committee of the American Society of Anesthesiologists position statement. <i>Anesth Analg</i>. 2019;129(2):347-349. doi:10.1213/ANE.0000000000004257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/31166228/pubmed" id="31166228" target="_blank">31166228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30858642">
<a name="30858642"></a>van Rensburg R, Decloedt EH. An approach to the pharmacotherapy of neuroleptic malignant syndrome. <i>Psychopharmacol</i>
<i>Bull</i>. 2019;49(1):84-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/30858642/pubmed" id="30858642" target="_blank">30858642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6893628">
<a name="6893628"></a>Wan HH, Tucker JS. Dantrolene and lymphocytic lymphoma. <i>Postgrad Med J</i>. 1980;56(654):261-262. doi:10.1136/pgmj.56.654.261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/6893628/pubmed" id="6893628" target="_blank">6893628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3527659">
<a name="3527659"></a>Ward A, Chaffman MO, and Sorkin EM, “Dantrolene: A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use in Malignant Hyperthermia, the Neuroleptic Malignant Syndrome and an Update of Its Use in Muscle Spasticity,” <i>Drugs</i>, 1986, 32(2):130-68.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/3527659/pubmed" id="3527659" target="_blank">3527659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3826671">
<a name="3826671"></a>Weingarten AE, Korsh JI, Neuman GG, et al, "Postpartum Uterine Atony After Intravenous Dantrolene," <i>Anesth Analg</i>, 1987, 66(3):269-70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/3826671/pubmed" id="3826671" target="_blank">3826671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-761834">
<a name="761834"></a>Wilkinson SP, Portmann B, Williams R. Hepatitis from dantrolene sodium. <i>Gut</i>. 1979;20(1):33-36. doi:10.1136/gut.20.1.33<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/761834/pubmed" id="761834" target="_blank">761834</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13203 Version 328.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
